Intact fibrin network
A native structural scaffold that stays on the skin — not a liquid that oxidizes, migrates and leaves with the serum.
Design concept only — this product does not exist and is not for sale. Not evaluated, cleared, or approved by the FDA. Illustrative mock-up; no medical claims are made.

Autologous whole blood clot
FastSkin Patch® Derm turns 20 mL of your patient’s own blood into a self-supporting autologous whole blood clot — applied directly to the skin. No centrifuge. No capital equipment. No compromise on what stays in.

The problem
PRP. PRF. Exosomes. Polynucleotides. Skin boosters. Every quarter brings a new vial and a new promise, and most of them share the same problem: you can’t see what’s in it, you can’t verify what it does, and you can’t defend it when a patient asks.
FastSkin Patch Derm is built on the opposite premise. You draw the blood. You watch it form. You place it yourself. Nothing is added, nothing is discarded, nothing is taken on faith.
Composition
Platelet-rich plasma does exactly what its name says: it separates platelets from the rest of the blood and discards the remainder. Leukocytes. Viable cells. Native proteins. The fibrin architecture that held it all together.
FastSkin Patch Derm uses whole blood. Every autologous component stays where biology put it — platelets, leukocytes, native exosomes and viable cells, organized within an intact fibrin network.

A native structural scaffold that stays on the skin — not a liquid that oxidizes, migrates and leaves with the serum.
Platelets, leukocytes, native exosomes and viable cells, preserved together rather than fractionated apart.
Growth factors and cytokines released over time from a scaffold in place, not delivered in a single liquid pass.
Comparison
| FastSkin Patch Derm | PRP | PRF | Exosome products | |
|---|---|---|---|---|
| Source | Patient’s whole blood | Patient’s blood, fractionated | Patient’s blood, fractionated | Allogeneic / donor-derived |
| Composition | All autologous components | Platelet concentrate | Platelets + fibrin | Varies by manufacturer |
| Physical form | Self-supporting clot | Liquid | Semi-solid | Liquid |
| Equipment required | None | Centrifuge | Centrifuge | None |
| Total time | Under 15 min | 20–30 min | 20–30 min | Minutes |
| Capital investment | $0 | $3,000–15,000 | $3,000–15,000 | $0 |
Mechanism

Compromised or freshly injured skin lacks a coherent provisional scaffold. FastSkin Patch Derm places a fresh, biologically relevant structure directly where the skin needs to rebuild.
An intact fibrin network provides native architecture supporting cellular proliferation and migration — the same structure the body builds for itself, delivered intact rather than reconstituted.
Platelets, leukocytes, native exosomes and viable cells provide sustained release of growth factors and cytokines that modulate the local environment and support the skin’s own repair process.
The procedure
20 mL of the patient’s blood, standard sterile kit.
Under 10 minutes. No centrifuge, no capital equipment.
Trim the self-supporting clot to the treatment area.
Place directly on the skin.
If your team can draw blood, your team can do this. Most practices are running it independently after a single training session.
Practice economics
Frequently asked
Book a demo
Fifteen minutes, one of our clinical specialists, and a live preparation in your own practice. No presentation.